Roivant Sciences Ltd

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Roivant Sciences reports strong Q1 earnings and explores new opportunities

Roivant Sciences demonstrated strong financial performance, with positive results for key programs and a substantial cash position. While facing challenges in patent litigation and DTC campaign optimization, the company has opportunities to leverage payer work, explore new therapeutic potentials, and capitalize on transaction opportunities.

ROIV reports positive trial results and potential in autoimmune diseases

ROIV's earnings call highlights positive trial results, potential in autoimmune diseases, and upcoming Phase III study results. The company acknowledges challenges in proving efficacy in lupus but is optimistic about brepocitinib's potential in various indications.

Roivant Sciences doubles revenue in Q3, VTAMA gains traction

Roivant Sciences delivered strong financial results and progress in its pipeline, particularly with the successful launch of VTAMA and enrollment in key studies.
While facing challenges in market penetration and patient behavior trends, the company's strategic focus on innovation and financial discipline positions it for future success.
By leveraging opportunities in expanding indications, advancing pipeline assets, and strategic collaborations, Roivant is poised for sustained growth and value creation.

Roivant Sciences reports robust Q4 earnings and strategic growth outlook

Roivant Sciences delivered a strong financial performance with notable achievements in clinical programs and a robust cash position, indicating stability and growth potential.
While facing challenges in patient consent for biomarker analysis and legal uncertainties, the company is strategically positioned to leverage opportunities in expanding its pipeline and exploring new markets.
With a focus on balancing operational challenges and pursuing strategic growth initiatives, Roivant Sciences remains well-positioned for future success in the biopharmaceutical industry.

Roivant Sciences excels in Q1 2024 with promising autoimmune therapies

Roivant Sciences demonstrated strong performance and promising results in Q1 2024 across multiple programs
Brepocitinib's unique mechanism positions it as a potential leader in autoimmune therapies, with significant market opportunities
Capital decisions post-Immunovant data and pricing strategy alignment present challenges for Roivant
Opportunities lie in rapid commercial launches, blockbuster potential in orphan indications, and prescription acceleration strategies

Roivant Sciences excels in Q2 with $7B cash post-sale

Roivant Sciences delivered a solid performance in Q2 2024, showcasing financial strength, positive clinical outcomes, and strategic focus on value creation. While facing challenges in margin optimization and market competition, the company is well-positioned to leverage opportunities in unmet medical needs and strategic partnerships for growth.

Roivant Sciences reports strong Q3 performance and outlines growth plans

Roivant Sciences showcased strong performance with key successes and efficient development models. The company faces challenges in certain clinical trials but remains optimistic about growth opportunities. By focusing on strategic growth and efficient execution, Roivant aims to capitalize on its promising pipeline and commercial potential.

Roivant Sciences excels in Q4, eyes blockbuster sales and strategic partnerships

Roivant Sciences is strategically positioned with a focus on maximizing pipeline opportunities, prioritizing data-driven decisions, and capitalizing on the differentiation potential of brepocitinib.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific

Fidelity National Information

Twilio

Workday

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed his portfolio for the final quarter of 2021 last week.

Andreas Halvorsen Loads Up on Health Care, Tech Stocks

Roivant Sciences Ltd. (ROIV) CEO Matt Gline on Q3 2022 Results - Earnings Call Transcript

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the third fiscal quarter ended December 31, 2021 and provided an update on the Company's operations.

Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 14, 2022 to report its third quarter 2021 financial results and provide a corporate update.

Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022

NEW YORK & SUZHOU & SHANGHAI, China--(BUSINESS WIRE)--TandemAI announced it has expanded its senior leadership team with the appointments of Albert Pan, Ph.D. to CTO and Lanny Sun to Chairman

TandemAI Announces Expansion of Senior Leadership Team

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001 (also known as H3B-8800), which will provide the lead program for a new subsidiary Vant.

Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference

BOSTON & BRUSSELS & SHANGHAI--(BUSINESS WIRE)--Full-Life Technologies, a new, fully integrated nuclear health company, announces senior executive team appointments

Full-Life Technologies Announces Senior Executive Team Appointments

Roivant Sciences Ltd.'s (ROIV) CEO Matthew Gline on Q2 2021 Results - Earnings Call Transcript

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the second fiscal quarter ended September 30, 2021 and provided an update on the Company's operations.

Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update

BASEL, Switzerland, LONDON, NEW YORK and BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 15, 2021 to report its second quarter 2021 financial results and provide a corporate update.

Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021

NEW YORK & BOSTON--(BUSINESS WIRE)-- #biotech--Roivant Discovery announces 2021 Open Science Fellows – Dr. Gregory R. Bowman, Dr. Alex Dickson and Dr. Paul Robustelli.

Roivant Discovery Announces 2021 Open Science Fellows

Three analysts initiated positive coverage on the biotech stock.

News for Roivant Sciences Ltd Stock (ROIV)